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Induction of lipolysis in murine white adipocytes, and stimulation of adenylate cyclase in adipocyte plasma membranes, by a
tumour-produced lipid mobilizing factor, was attenuated by low concentrations (10
77–10
75 M) of the speciﬁc b3-
adrenoceptor antagonist SR59230A. Lipid mobilizing factor (250 nM) produced comparable increases in intracellular cyclic
AMP in CHOK1 cells transfected with the human b3-adrenoceptor to that obtained with isoprenaline (1 nM). In both cases
cyclic AMP production was attenuated by SR59230A conﬁrming that the effect is mediated through a b3-adrenoceptor. A
non-linear regression analysis of binding of lipid mobilizing factor to the b3-adrenoceptor showed a high afﬁnity binding site
with a Kd value 78+45 nM and a Bmax value (282+1 fmole mg protein
71) comparable with that of other b3-adrenoceptor
agonists. These results suggest that lipid mobilizing factor induces lipolysis through binding to a b3-adrenoceptor.
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Patients with cancer cachexia experience a dramatic loss of body fat
as the condition progresses. A study of the body composition of
lung cancer patients, who had lost 30% of their pre-illness stable
weight, showed an 85% decrease in total body fat (Fearon,
1992), reﬂecting a prolonged catabolic state. Cancer patients with
weight loss have been found to have an elevated level of a lipid
mobilizing factor (LMF) in both serum and urine, which appears
to parallel the weight loss (Groundwater et al, 1990). We have
isolated LMF from the urine of cancer patients by a combination
of ion exchange, exclusion and hydrophobic interaction chromato-
graphies, and shown it to be homologous with the plasma protein
Zn-a2-glycoprotein (ZAG) in primary sequence, electrophoretic
mobility and immunoreactivity (Todorov et al, 1998). In vivo
studies conﬁrmed the ability of LMF to cause selective loss of
carcass fat with no change in body water, and a tendency to
increase the nonfat mass. LMF was characterized by the ability to
stimulate lipolysis directly in isolated adipocytes, as a result of
stimulation of adenylate cyclase in a GTP-dependent process (Hirai
et al, 1998). The receptor for this interaction has not been charac-
terized, but indirect evidence suggests that it may be a b3-
adrenergic receptor (b3-AR).
Thus treatment of ob/ob mice with LMF, not only produced a
speciﬁc depletion of the adipose mass together with an elevation
of serum glycerol levels, but also an increased oxygen uptake by
interscapular brown adipose tissue (BAT) (Hirai et al, 1998). Phar-
macological studies indicate that the b-receptor responsible for the
stimulation of oxygen consumption in BAT is exclusively of the
b3-subtype (Howe, 1993). Induction of lipolysis in epididymal
adipocytes by LMF was attenuated by the b-adrenergic receptor
blocker propranolol (Khan and Tisdale, 1999), while the biphasic
effect of GTP on cyclic AMP production by LMF in adipocyte
plasma membranes suggests a receptor associated with both Gs
and Gi. Only b3 and not b1-AR interact with Gi in adipocyte
membranes (Granneman, 1995).
In the present study the ability of LMF to interact with the b3-
AR has been studied both in white adipocytes and in CHO cells
transfected with the human b3-AR.
MATERIALS AND METHODS
Patients
Urine was collected over a 24 h period from patients with unre-
sectable pancreatic cancer and with a weight loss between 0.5
and 3 kg month
71. No patient had received radiotherapy or
chemotherapy. Urine samples were stored at 7208C in the absence
of preservatives prior to use.
Chemicals
[a-
32P]-ATP (sp. act. 20 Cimmol
71) and Na [
125I] (sp. act.
415 Cimg
71 iodide) were purchased from Amersham Pharmacia
Biotech (Bucks, UK). SR59230A was kindly donated by Dr L
Manara of the Research Centre Sanoﬁ Midy, Sanoﬁ Winthrop
S.p.A., Milan, Italy.
Puriﬁcation of LMF
LMF was puriﬁed from human urine using a combination of batch
extraction on DEAE-cellulose and hydrophobic interaction chro-
matography (Todorov et al, 1998). Urine was centrifuged at
3000 g for 10 min to remove particulate material and was then
diluted with 4 vol 10 mM Tris HCl, pH 8.0. DEAE-cellulose,
previously activated by washing in 100 mM Tris HCl, pH 8.0 for
5 min was added to the diluted urine (10 g l
71 of original urine)
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recovered by sedimentation by low speed centrifugation, and the
LMF was eluted with 0.5 M NaCl in 10 mM Tris HCl, pH 8.0.
The eluate was equilibrated and concentrated to 1 ml by ultraﬁltra-
tion, in an Amicon ﬁltration cell (Millipore (UK) Ltd, Watford,
Herts, UK) containing a membrane ﬁlter with a molecular weight
cut-off of 10 kDa, against PBS. Further puriﬁcation was achieved
using a Resource-Iso HPLC column (Pharmacia Biotech, St Albans,
Herts, UK), employing a decreasing (NH4)2SO4 concentration from
1.5 M. Active fractions containing LMF eluted at 0.6 M (NH4)2SO4,
and were desalted before use by washing ﬁve times against PBS
using an Amicon ﬁltration cell.
Lipolytic assay
A single cell suspension of white adipocytes was prepared from the
epididymal adipose tissue of ex-breeder male NMRI mice using
collagenase digestion (Beck and Tisdale, 1987). Lipolytic activity
was determined by measuring glycerol release (Wieland, 1974) after
incubation of LMF with 10
572610
5 adipocytes for 2 h at 378Ci n
1 ml Krebs-Ringer bicarbonate buffer, pH 7.2. Control samples
containing adipocytes alone were analyzed to determine the spon-
taneous glycerol release. Lipid mobilizing activity was expressed as
mmole glycerol released 10
5 adipocytes
71 2h
71.
Adenylate cyclase assay
Plasma membranes were isolated from epididymal adipocytes, as
previously described (Khan and Tisdale, 1999). Brieﬂy isolated
adipocytes were homogenized in 250 mM sucrose, 2 mM EGTA
and 10 mM Tris HCl pH 7.4, followed by centrifugation at
30000 g for 1 h at 48C. The membrane pellet formed was isolated
and separated from other organelle membranes on a self forming
Percoll gradient, and the mixture was centrifuged at 10000 g for
30 min at 48C. The washed plasma membranes were diluted in
10 mM Tris HCl, pH 7.4, containing 250 mM sucrose, 2 mM EGTA
and 4 mM phenylmethylsulphonylﬂuoride at 1–2 mg ml
71, and if
not used immediately, snap frozen in liquid nitrogen and stored at
7708C until use. The adenylate cyclase assay was based on that
developed by Salomon et al (1973) as previously described (Hirai
et al, 1998). Brieﬂy LMF was incubated for 10 min at 308C
together with plasma membrane in 25 mM Tris HCl, pH 7.5,
5m M MgCl2,1 0 mM GTP, 8 mM creatine phosphate, 16 units
ml
71 creatine phosphokinase, 1 mM 3-isobutyl-1-methylxanthine
and 1 mM [a-
32P]-ATP (sp.act. 20 Cimmole
71) in a total volume
of 100 ml. The reaction was terminated by the addition of 2%
SDS, 40 mM ATP and 1.4 mM cyclic AMP. The cyclic AMP was
isolated from the mixture using a combination of Dowex 50W8-
400 and Alumina WN-3 columns, and the radioactivity was deter-
mined using a Tri-carb 2000A scintillation counter.
Cyclic AMP determination
CHOK1 cells transfected with the human b3-AR, under the control
of hygromycin, together with the b-gal reporter construct, selected
for resistance to G418, were a gift from Dr Ian Waddell, Astra
Zeneca, Macclesﬁeld, Cheshire, UK. They were grown in Dulbec-
co’s modiﬁed Eagles medium (DMEM) supplemented with 2 mM
glutamine, 50 mg ml
71 hygromycin B and 200 mg ml
71 G418,
under an atmosphere of 10% CO2 in air. For cyclic AMP assays
cells were grown in 24 multi-well plates in 1 ml DMEM. Agonists
were added to the wells and incubated for 30 min, after which the
medium was removed and 0.5 ml 20 mM HEPES, pH 7.5, 5 mM
EDTA and 0.1 mM isobutylmethylxanthine was added to each well.
The plate was placed in a boiling water bath for 5 min and cooled
on ice for 10 min. To 50 ml of the cell extract was added 2 mCi of
[8-
3H]-cyclic AMP (Amersham, UK) and 20 mg of cyclic AMP-
dependent protein kinase (Sigma Chemical Co. Ltd, Dorset, UK)
and incubated for 2 h at 48C. Unbound cyclic AMP was removed
by adsorption onto charcoal and the concentration of cyclic AMP
in the sample determined by comparison with standard curves
using known concentrations of cyclic AMP.
Iodination of LMF with [
125I]
One iodo-bead (Pierce and Warriner, Chester, UK), washed and
dried, was incubated with Na[
125I] (1 mCi per 100 mg protein)
for 5 min in 100 ml PBS. LMF (100 mg protein) was then added
and the reaction allowed to proceed for 15 min. The iodo-bead
was physically removed and free Na[
125I] was removed using a
Sephadex G25 column eluted with 0.1 M NaI. The [
125I] LMF
was concentrated using a Microcon microconcentrator with a Mr
10000 cut-off against PBS.
Binding studies
CHOK1 cells transfected with the human b3-AR were lysed by
sonication in 0.5 M MgCl2,2 m M Tris HCl, pH 7.5 and crude
membranes were pelleted by centrifugation (45000 g, 15 min,
48C). Binding studies were conducted in 400 ml 0.5 mM MgCl2
50 mM Tris HCl, pH 7.5, by incubation of membranes (50 mg
protein) with various concentrations of [
125I] LMF for 60 min at
378C. The samples were then centrifuged at 13000 g for 20 min,
the supernatant was removed and the radioactivity of the pellet
was determined using a Packard Cobra Model 5005 Auto-gamma
counter. Binding was analyzed using non-linear regression analysis
(GraphPad Prism, Version 3.00 for windows, GraphPad Software
(San Diego, CA, USA)).
RESULTS
LMF induced a direct lipolytic response in murine white adipo-
cytes, and this effect was attenuated by low concentrations
(10
75–10
77 M) of SR59230A (Figure 1A), which has been
reported to have a 10-fold selectivity for the b3-AR over the b1-
AR (Nisoli et al, 1996). Induction of lipolysis by LMF was asso-
ciated with a stimulation of adenylate cyclase in isolated
adipocyte membranes in the presence of 0.1 mM GTP, and this
action was almost completely inhibited by SR59230A at concentra-
tions as low as 10
79 M (Figure 1B). The difference in sensitivity of
intact adipocytes and plasma membranes may be related to access
of SR59230A to the b3-AR. SR59230A has been shown to bind
strongly to albumin (Nisoli et al, 1996) reducing the effective
concentration available in the adipocyte assay. These results suggest
that LMF stimulates lipolysis through interaction with a b3-AR.
To investigate this possibility the effect of LMF on cyclic AMP
production was determined in CHOK1 cells, which had been trans-
fected with the human b3-AR. The data presented in Figure 2
shows that both isoprenaline and LMF stimulated cyclic AMP
production, which reached a comparable maximum level of
25 pmoles per 10
6 cells with both agents. However maximal cyclic
AMP production was achieved with much lower concentrations of
isoprenaline (1 nM) than LMF (250 nM), suggesting that LMF had
a lower afﬁnity for the b3-AR than isoprenaline. The increase in
intracellular cyclic AMP produced by both isoprenaline and LMF
in CHOK1b3 was attenuated by the non-speciﬁc b-AR antagonist
propranolol (10 mM), while the effect on LMF, although signiﬁcant,
was less than complete. However, cyclic AMP production by both
isoprenaline and LMF was almost completely attenuated by
SR59230A, conﬁrming that the action of LMF was mediated
through a b3-AR.
To determine the afﬁnity of binding of LMF to the b3-AR, LMF
was radioiodinated with
125I and the binding to crude plasma
membranes from CHOK1b3 cells was determined. The data is
presented in Table 1. Non-linear regression analysis of binding
showed a high afﬁnity binding site for LMF with a Kd value about
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ã 2002 The Cancer Research Campaign British Journal of Cancer (2002) 86(3), 424–428100-fold lower than that of CGP 12177, a partial agonist of b3-AR
(Kubo et al, 1997) and [
125I] iodocyanopindolol (Hutchinson et al,
2000), commonly used in binding studies with b3-AR. However,
the Bmax value for LMF was similar to that for other b3-AR
agonists. Binding of [
125I] LMF was signiﬁcantly reduced in the
presence of non-labelled LMF, the non-speciﬁc b-AR antagonist
propranolol and the selective b3-AR antagonist SR59230A (Table
1). These results conﬁrm that LMF binds to a b3-AR and stimu-
lates adenylate cyclase.
DISCUSSION
Resting energy expenditure (REE) has been reported to be signiﬁ-
cantly increased in weight losing patients with lung (Fredrix et al,
1990) and pancreatic cancer (Falconer et al, 1994). Hyltander et al
(1991) found that cancer patients had an elevated REE and
increased fat oxidation compared with either weight losing or
weight stable controls, and that this was related to an increased
heart rate. Such patients were also found to exhibit an increased
cardiovascular and metabolic response to adrenaline infusion
(Drott et al, 1987), while administration of the non-speciﬁc b-
blocker propranolol was found to produce a decrease in the basal
metabolic rate (BMR) (Gambardella et al, 1999). These results led
to the hypothesis of overactivity of the sympathetic nervous system
(SNS) in cancer patients.
Classical b1 and b2-AR mediate response to noradrenaline
released from the SNS. In addition a third b-AR subtype has been
identiﬁed (reviewed in Howe, 1993), which shares only 40–50%
amino acid sequence identity with b1 and b2-AR, and is referred
to as a b3-AR. These receptors mediate lipolysis in white adipose
tissue in mice and rats (Arch et al, 1984; Arch and Wilson,
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Figure 1 (A) Effect of the b3-AR antagonist SR59230A on lipolysis in
murine white adipoctes; induced by LMF. Adipocytes were preincubated
with the indicated concentration of SR59230A for 30 min prior to the
addition of LMF (465 nM). (B) Effect of SR59230A on the stimulation of
adenylate cyclase in isolated murine adipocyte plasma membranes by
LMF. Membranes were preincubated with the indicated concentrations
of SR59230A for 30 min prior to the addition of LMF (2.35 mM) and ade-
nylate cyclase was determined as described in Materials and Methods in the
presence of 0.1 mM GTP. The results are expressed as means +s.d. and the
data is representative of three separate experiments. Differences from in-
cubation in the absence of SR59230A is indicated c, P50.005 and d,
P50.001 as determined by Student’s t-test.
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Figure 2 Effect of LMF (A) and isoprenaline (B) on cyclic AMP levels in
CHOK1b3 cells in the absence (*) or presence of 10 mM propranolol (*)
or 10 mM SR59230A (~) Differences from controls are indicated as b,
P50.01 and d, P50.001 as determined by ANOVA.
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responsible for the unexpected negative inotropic effects of cate-
cholamines in the heart (Gauthier et al, 1996). However, the
evidence that b3-AR can mediate lipolysis in human adipocytes
is controversial, since b3-AR mRNA is expressed at a much lower
level than in rat or mouse (Langin et al, 1991), although lipolysis
has been induced in human omental fat cells by the selective b3-
AR agonist CGP 12177 (Hoffstedt et al, 1995), and LMF (Hirai
et al, 1998).
We have previously shown that cachexia in both mice and
humans is associated with LMF production by the tumour and
excretion in the urine (Todorov et al, 1998), and that LMF stimu-
lated lipolysis like a classical lipolytic hormone through increases
in intracellular cyclic AMP as a result of the stimulation of adeny-
late cyclase (Hirai et al, 1997). This study shows that LMF exerts
this effect through a b3-AR, although the afﬁnity for this receptor
appears to be less than seen with classical b3-AR agonists. In
white adipocytes both the induction of lipolysis and the stimula-
tion of adenylate cyclase were attenuated by the b3-AR antagonist
SR59230A (Nisoli et al, 1996), while in CHO cells transfected with
the human b3-AR LMF stimulated cyclic AMP production in a
similar manner to isoprenaline, although the concentration
required to produce maximal stimulation was 250-fold greater.
In addition SR59230A attenuated the increase in cyclic AMP
conﬁrming the effect was mediated through a b3-AR. The effect
of propranolol was less complete than with isoprenaline, suggest-
ing that the mechanism of stimulation by LMF may be different.
Previous studies (Khan and Tisdale, 1999) have shown proprano-
lol to act as a non-compedative inhibitor of the induction of
lipolysis in murine white adipocytes by LMF. This suggests that
it may act at a site distal to the b3-AR and may attenuate the
action of two b3 agonists to different extents. In this study we
have used intact cells, since the coupling efﬁciency of b3-AR to
adenylate cyclase is highly dependent upon the integrity of the
cells (Granneman, 1995). However, it is known that the coupling
efﬁciency of b3-AR is greater than that for b1-AR, thus offsetting
the low binding afﬁnity. Also unlike b1 and b2-AR the b3-AR has
fewer potential phosphorylation sites and is resistant to agonist-
induced desentitization (Granneman, 1995). The b3-AR mediated
coupling of LMF to lipolysis would explain the lowered maximal
response of human omental adipocytes to lipolysis when
compared with murine white adipocytes (Hirai et al, 1998).
However, the increased coupling efﬁciency together with the
induction of UCP1 in brown adipose tissue (BAT) (Russell et
al, 2000) would ensure maximum fat mobilization and utilization
together with a net increase in energy expenditure. These results
suggest that selective b3-AR antagonists may be useful in control-
ling energy expenditure and fat mobilization in cancer cachexia.
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